Chiltern International's programme of recruitment continues with the announcement that Ajaz Qureshi has joined the firm's headquarters as an early phase business development executive
Ajaz Qureshi has joined Chiltern after a four and a half year period with Quintiles, where he began by working with the clinical team running Phase I clinical trials and then moved into business development as an associate.
He is the latest in a series of business development appointments made by the Chiltern throughout mainland and continental Europe and in the United States.
Qureshi believes the industry will be impressed with Chiltern's expertise in relation to the new European Union Directive, commenting: "One of the critical issues facing everyone in the industry is the implementation of the EU Directive on Phase I clinical trials.
"Chiltern International has worked hard to be able to offer the industry the regulatory support to ensure Phase I studies can be conducted in the UK without delay and this will undoubtedly prove to be a major asset in the future".
Established in London in 1982, clinical research organisation Chiltern International provides clinical operations, project management, data management, biostatistics, medical writing, quality assurance and regulatory and medical affairs services to the pharmaceutical, biotechnology and medical device industries.
The company offers clinical contract personnel services to pharmaceutical and biotechnology clients.
It has 12 international offices - three in the United States and nine in Europe.
